While Others Stall on Obesity, Zafgen Accelerates with $33M
By Catherine Shaffer
Thursday, July 7, 2011
Tom Hughes, President and CEO of Zafgen Inc., is not concerned about the FDA's upcoming general advisory committee in 2012 to address requirements for cardiovascular assessments for obesity therapeutics. Whereas the announcement has left late-stage obesity companies like Orexigen Therapeutics Inc., Vivus Inc. and Arena Pharmaceuticals Inc. in a sort of limbo, Cambridge, Mass.-based Zafgen is moving forward with confidence.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.